| 摘要 |
<p>Anti human HER2 monoclonal antibodies are disclosed. Preferably, the anti HER2 monoclonal antibodies comprise fully human light and/or heavy chain variable region derived from molecular evolution. The use of a pharmaceutical composition comprising the human antibodies for treating immune or other diseases related to HER2 is also disclosed.</p> |
